SONAR is a multinational, double-blind, placebo-controlled clinical study that is expected to enroll more than 4,000 patients with diabetic nephropathy...Destiny Pharma Ltd., of Brighton, UK, reported progress in the Phase I U.S

clinical trials, for SMD and dry age-related macular degeneration (dry AMD...BHR Pharma LLC, of Herndon, Va., said the 1,000th patient has been enrolled in its SyNAPSe clinical trial, a global Phase III study evaluating the effectiveness of its intravenous progesterone infusion agent, BHR-100, to treat severe traumatic brain injury (TBI...BHR Pharma is sponsoring SyNAPSe with the intent to bring the first-ever approved TBI treatment to market

The randomized, double-blind, placebo-controlled trial will enroll 108 patients at about 30 sites in the U.S...Cerulean Pharma Inc., of Cambridge, Mass., will present Phase II data for investigational nanopharmaceutical product CRLX101 at the American Association for Cancer Research Annual Meeting

The randomized, double-blind, placebo-controlled trial will be carried out in the UK with a primary objective of safety and tolerability of single and multiple doses of subcutaneous ALN-TTRsc...The double-blind, randomized, placebo-controlled trial will assess safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple-escalating doses of the drug in healthy adults

The randomized, double-blind trial at 11 sites in North America and Europe involved 1,012 patients with acute ST-segment elevation myocardial infarction (STEMI) without a history of HF or EF < 40 percent and without signs of HF...Findings were presented during the late-breaking clinical trial session at the American College of Cardiology 62nd Annual Scientific Session in San Francisco

Polyphor Ltd., of Allschwil, Switzerland, completed a Phase I trial demonstrating the clinical safety and tolerability of its Pseudomonas-specific antibiotic POL7080...All primary study objectives were achieved in the randomized, double-blind, placebo-controlled dose-escalation trial assessing the safety, tolerability and pharmacokinetics of POL7080 in 52 healthy male volunteers

Amicus Therapeutics Inc., of Cranbury, N.J., reported positive results from clinical and preclinical studies of the pharmacological chaperone AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease at the Lysosomal Disease Network World Symposium...Based on those results, the company plans to initiate a repeat-dose clinical study in the third quarter of 2013 to evaluate an intravenous formulation of AT2220 co-administered with Myozyme/Lumizyme...BioAlliance Pharma SA, of Paris, said the FDA

The randomized, double-blind, placebo-controlled trial will enroll about 300 previously treated patients with MET-high inoperable HCC to receive tivantinib or placebo, with a primary endpoint of overall survival and a secondary endpoint of progression-free survival. (See BioWorld Today, Oct. 3, 2012, and Jan. 13, 2013...Cerulean Pharma Inc., of Cambridge, Mass., said the first patient was dosed in a Phase II study of CRLX101, a nanopharmaceutical designed to inhibit both topoisomerase 1 and hypoxia

EyeGate Pharma Inc., of Waltham, Mass., said it enrolled the last patient in a 200-subject pivotal Phase III study of EGP-437 (dexamethasone phosphate ophthalmic solution) in patients with anterior uveitis...The randomized, double-blind, placebo-controlled study will assess efficacy and safety of two doses of Nefecon in 90 patients with primary IgA nephropathy who are at risk for end-stage renal disease

Acasti Pharma Inc., of Laval, Quebec, said it achieved significant progress in two ongoing clinical studies with CaPre for lipid management...The registrational Phase II double-blind, placebo-controlled clinical study has completed the first of two interim analyses

Infinity has moved IPI-145 into a randomized, double-blind, placebo-controlled, multidose, crossover Phase IIa study in asthma, and a Phase II study in RA is planned...OncoSec plans to use the proceeds to fund clinical trials and research and development and for other corporate purposes...The company plans to use the proceeds to fund research and development, clinical trials and for other corporate purposes.

BioAlliance Pharma SA, of Paris, said the European Independent Board of Experts held its first meeting on the ReLive Phase III trial of Livatag (doxorubicin transdrug) in primary liver cancer and recommended continuing the study without modification...Clavis Pharma ASA, of Oslo, Norway, said it reached the enrollment target for its Phase III CLAVELA study investigating elacytarabine in patients with relapsed or refractory acute myeloid leukemia (AML...with experience and expertise in stem cell

NeuroVive Pharmaceutical AB, of Lund, Sweden, said Phase I data published in Clinical Drug Investigation showed that its CicloMulsion, a Cremophor-free intravenous cyclosporine formula, was bioequivalent to Sandimmune injection and was safe and well tolerated...CicloMulsion is a cyclophilin inhibitor in clinical development to treat cardiac reperfusion injury and, under the name NeuroSTAT, in development for traumatic brain injury...Noxxon Pharma AG, of Berlin, said it treated the first patients in a

The randomized, double-blind, placebo-controlled, parallel-group, multicenter trial will be conducted at 60 sites in the U.S...The FDA gave permission to Isotechnika Pharma Inc., of Edmonton, Alberta, to begin two Phase III trials of voclosporin, in kidney transplant

CellAct Pharma GmbH, of Dortmund, Germany, said its topoisomerase inhibitor CAP7...The double-blind, placebo-controlled trial enrolled 280 patients at eight centers in the U.S. Patients receive a 25-mg dose of OCA or placebo for 72 weeks

The Phase III study met its primary endpoint and demonstrated statistically significant protection against clinical and severe malaria in infants...In a two-week, randomized, double-blind, placebo-controlled study, 715 patients with SAR, 6-11 years, received once-daily treatment with QNASL 80 mcg, 160 mcg or placebo

The randomized, double-blind, placebo controlled trial measured benefit in overall survival compared to placebo...The double-blind, randomized study in 40 patients will produce top-line data by the middle of 2013

Meritage Pharma Inc., of San Diego, began a Phase II trial of oral budesonide suspension for eosinophilic esophagitis...The double-blind, randomized, placebo-controlled trial will enroll 100 patients between 12 and 25 with confirmed EoE and problems swallowing food

Clavis Pharma ASA, of Oslo, Norway, said its partner Clovis Oncology Inc., of Boulder, Colo., initiated a Phase I study of CP-4126 (CO-101) in combination with cisplatin in non-small-cell lung cancer (NSCLC...The randomized, double-blind, placebo-controlled, single-center trial will investigate the safety and pharmacokinetics of single and multiple ascending doses of 3K3A-APC in healthy adult volunteers, with results expected in the first quarter of 2013